A Phase II, Randomized, Double-blind, Placebo-controlled, Parallel-group Proof-of-concept Study to Evaluate Efficacy and Safety of Distal Jejunal-release Dextrose (Aphaia Technology, AT) in Obese Subjects
Latest Information Update: 31 Oct 2025
At a glance
- Drugs Distal-jejunal-release-dextrose-beads (Primary)
- Indications Obesity
- Focus Proof of concept; Therapeutic Use
- Sponsors Aphaia Pharma
Most Recent Events
- 09 Sep 2025 Results presented in an Aphaia Pharma media release
- 16 Oct 2024 Planned End Date changed from 30 Mar 2024 to 11 Nov 2024.
- 16 Oct 2024 Planned primary completion date changed from 30 Mar 2024 to 11 Nov 2024.